A number of well-known pharmaceutical companies have been sold (attached list)
▍ Source: Announcement of Pharmaceutical Companies
▍ Finishing: Cypress Blue-Corn
▍ Industry concentration has been further improved.
In 2019, there were frequent mergers and acquisitions between pharmaceutical companies. Observing these cases, we can find that some of them spun off their subsidiaries and some strengthened their own strengths through acquisitions. In addition, the sale of non-core assets by foreign pharmaceutical companies and the takeover by domestic pharmaceutical companies have also caused industry analysis.
In these cases, some of them have been completed and some are still in progress. Through the inventory of one-year acquisition cases, it seems that the industry is progressing in the direction of increasing concentration.
With the deepening of medical reform, the implementation of policies such as consistency evaluation, quantity procurement and DRG, and the improvement of industry access threshold, SMEs will be acquired more frequently by large enterprises.
Of course, this is just like the plan of "supporting the merger and reorganization of pharmaceutical production enterprises, cultivating a number of large enterprise groups with international competitiveness, and improving the concentration of pharmaceutical industry" in the "Several Opinions on Further Reforming and Improving the Policy of Drug Production, Circulation and Use" issued by the State Council in early 2017.
Suzhou Novartis completed the sale.
On December 21st, Zhejiang Jiuzhou Pharmaceutical Co., Ltd. issued the Announcement on Completion of 100% Equity Delivery of Suzhou Novartis Pharmaceutical Technology Co., Ltd., and formally merged Suzhou Novartis into its subsidiary.
Jiuzhou Pharmaceutical announced on November 30 that the board of directors passed the Proposal on Foreign Investment to Buy 100% Equity of Suzhou Novartis Pharmaceutical Technology Co., Ltd., and estimated to buy 100% equity of Suzhou Novartis held by Novartis Investment with self-raised funds of about 790 million yuan.
According to the data, Suzhou Novartis acquired by Jiuzhou Pharmaceutical Co., Ltd. mainly consists of factory buildings, production lines, process equipment, etc. after divesting the technology and drug development assets held by Novartis.
Fosun Pharma sells assets for 3.6 billion yuan
On December 19th, Shanghai Fosun Pharma (Group) Co., Ltd. issued the Announcement on the Progress of Selling Assets and Foreign Investment, intending to transfer all the limited partnership interests of Healthy Harmony Holdings, L.P. (whose main assets are "United Family" hospitals and clinics) and the management partner of Healthy Harmony Holdings, L.P.. The consideration for this transfer is about US$ 523.15 million (equivalent to about RMB 3.6 billion).
Tasly sells Tasly Medicine Marketing Group.
On December 17th, Tasly announced that it had signed the Framework Agreement with Chongqing Pharmaceutical, and made an agreement on selling the equity of its holding subsidiary Tianjin Tasly Pharmaceutical Marketing Group.
According to the Framework Agreement, Chongqing Pharmaceutical intends to acquire 87.47% of the shares directly and indirectly held by the company and the shares held by other shareholders of Tianshi Marketing by paying cash consideration.
Nanjing pharmaceutical holding enhua herun
On December 13th, Nanjing Pharmaceutical Co., Ltd. issued the Announcement on Completion of Change Registration Procedures for Acquisition of Equity, indicating that the acquisition of Jiangsu Enhua Herun Pharmaceutical Co., Ltd. for 72.24 million yuan has completed the change registration procedures for shareholders and legal representatives. So far, Nanjing Pharmaceutical directly holds 70% equity of Enhua Herun.
China Resources Sanjiu acquires Aonuo Pharmaceutical.
On November 27th, China Resources Sanjiu Pharmaceutical Co., Ltd. issued the Announcement on Acquisition of 100% Equity of Aonuo (China) Pharmaceutical Co., Ltd., and planned to acquire 100% equity of Aonuo (China) Pharmaceutical Co., Ltd. held by Yuheng Pharmaceutical for 1.42 billion yuan.
According to the announcement, the core products of Aonuo Pharmaceutical are calcium zinc gluconate oral solution, vitamin C chewable tablets and Shenzhi Dendrobium granules, and its "Aonuo" and "Jinxin Jinjiute" are well-known brands for children to supplement calcium. China Resources Sanjiu said that the acquisition can improve the category layout of self-diagnosis and treatment (CHC), which can be organically combined with the advantages of China Resources Sanjiu in consumer insight, brand operation and terminal coverage.
Pfizer merged with Mylan.
On November 12th, Mylan and Pfizer officially announced the name of the new company-Via Tris, which was formed by the merger of Mylan and Pfizer’s subsidiary Pfizer Puqiang.
The 2018 financial report shows that Pfizer’s global revenue is $12.5 billion, and the China market contributes $2.4 billion. Mylan is a multinational giant, with a global revenue of 11.434 billion US dollars in 2018, and has not yet started business in China.
Da Shen Lin bought 123 chain pharmacies.
On November 7, Dashenlin Pharmaceutical Group Co., Ltd. issued the Announcement on Acquisition of 51% Equity of Nantong Jianghai Pharmacy Chain Co., Ltd., and plans to acquire 51% equity of Nantong Jianghai Pharmacy Chain Co., Ltd., with the target company including 123 chain pharmacies and the acquisition amount of 120 million yuan.
GSK sells Suzhou factory and Hepudin.
On July 8, Fosun Pharma announced that its holding subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., intends to acquire 100% equity of GlaxoSmithKline Pharmaceutical (Suzhou) Co., Ltd. for no more than RMB 250 million. If the transfer is completed, it will hold the drug registration approval of lamivudine tablets (specification: 0.1g) for the treatment of chronic hepatitis B and the production license and GMP certificate of its production facilities.
On July 9th, GSK China confirmed to Cyberland that both parties expected the transaction to be completed by the end of November.
Sinopharm Holdings acquired Anhui Pharmaceutical Group
On May 8, the official public platform of Sinopharm Holding Anhui Co., Ltd. released a message: Sinopharm Holdings officially signed a contract to acquire Anhui Pharmaceutical Group. According to public information, Anhui Pharmaceutical Group is a large-scale commercial circulation enterprise approved by the Anhui provincial government in December 2002.
China Resources Medicine Acquires Jiangzhong
On April 17, Jiangzhong Pharmaceutical Co., Ltd. announced that the company recently received a notice from the controlling shareholder of the company. With the approval of Jiangxi Provincial Market Supervision Administration, the controlling shareholder completed the industrial and commercial change registration of the enterprise name and business scope on April 8, 2019.
After the change, Jiangxi Jiangzhong Pharmaceutical (Group) Co., Ltd. was changed to China Resources Jiangzhong Pharmaceutical Group Co., Ltd. Jiangzhong Pharmaceutical said in its 2018 annual report that the brand value of "Jiangzhong" was 20.715 billion yuan, ranking 231st among the top 500 Chinese brands and 6th in the pharmaceutical industry. For China Resources Medicine, the acquisition of Jiangzhong Group won brands such as "Jiangzhong" and "Chuyuan".
Bristol-Myers Squibb acquires Xinji.
On January 3rd, Bristol-Myers Squibb announced a $74 billion acquisition of Xinji. According to the agreement between the two parties, Bristol-Myers Squibb will acquire Xinji Company in the form of $74 billion in cash and stock transactions to build a first-class biopharmaceutical giant that can compete with the world’s largest pharmaceutical manufacturer.
In fact, the merger and acquisition of pharmaceutical companies in 2019 is far more than that. By combing the actions of well-known enterprises, the purpose is to find the trend of industry changes under these mergers and acquisitions. In addition, in the announcements of many listed pharmaceutical companies selling assets this year, many properties were thrown out. Some analysts believe that pharmaceutical companies sell houses to survive, but a more rational view should be due to the limited value-added space of real estate.